EURORDIS Feedback to the European Commission Consultation on the EU Life Sciences Strategy
From March to April 2024, the European Commission held a public consultation to shape its forthcoming EU Life Sciences Strategy, a flagship initiative to boost competitiveness, drive innovation, and reduce strategic dependencies across sectors from health to agriculture.
To ensure rare diseases are central to this agenda, EURORDIS-Rare Diseases Europe submitted detailed feedback positioning rare conditions as a strategic entry point for advancing genomics, precision medicine, and advanced therapies in Europe.
The recommendations in our consultation feedback focus on:
- Bridging the research-to-access gap through investment, innovation funding, and regulatory reform.
- Supporting academic and SME developers, including through simplified pathways and technical infrastructure.
- Ensuring equity in access across Member States via joint procurement and real-world data.
- Embedding patient partnership in research, regulation, and innovation governance.
- Strengthening European Reference Networks (ERNs) and specialist centres as research and care hubs.
The Strategy, due in Q2 2025, will guide EU action through the current Commission term (to 2029).
EURORDIS’ full submission is available on our site , as well as on the European Commission portal.